Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
FATE Fate Therapeutics, Inc. daily Stock Chart
FATE [NASD]
Fate Therapeutics, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-1.31 Insider Own1.00% Shs Outstand73.60M Perf Week3.42%
Market Cap2.16B Forward P/E- EPS next Y-1.66 Insider Trans- Shs Float73.60M Perf Month20.33%
Income-85.90M PEG- EPS next Q-0.39 Inst Own96.50% Short Float13.00% Perf Quarter105.31%
Sales9.50M P/S227.46 EPS this Y-15.80% Inst Trans-2.22% Short Ratio9.55 Perf Half Y56.00%
Book/sh4.00 P/B7.34 EPS next Y-15.30% ROA-35.30% Target Price26.73 Perf Year104.74%
Cash/sh4.11 P/C7.14 EPS next 5Y- ROE-48.90% 52W Range12.59 - 29.86 Perf YTD50.03%
Dividend- P/FCF- EPS past 5Y-1.70% ROI-38.30% 52W High2.29% Beta2.04
Dividend %- Quick Ratio7.50 Sales past 5Y37.30% Gross Margin- 52W Low142.65% ATR1.31
Employees104 Current Ratio7.50 Sales Q/Q140.00% Oper. Margin- RSI (14)76.18 Volatility4.16% 4.90%
OptionableYes Debt/Eq0.05 EPS Q/Q-28.40% Profit Margin- Rel Volume0.72 Prev Close29.36
ShortableYes LT Debt/Eq0.00 EarningsMar 03 AMC Payout- Avg Volume1.00M Price30.55
Recom1.60 SMA2013.92% SMA5030.91% SMA20060.69% Volume511,473 Change4.05%
Jan-09-20Downgrade BMO Capital Markets Outperform → Market Perform $22
Dec-30-19Reiterated Mizuho Buy $27 → $33
Dec-09-19Upgrade Wells Fargo Market Perform → Outperform
Nov-12-19Initiated SunTrust Buy $25
Nov-06-19Downgrade Wells Fargo Outperform → Market Perform
Oct-01-19Initiated Stifel Buy $27
Aug-09-19Initiated BTIG Research Buy $27
Jul-22-19Initiated Cantor Fitzgerald Overweight
Jul-12-19Initiated Oppenheimer Outperform $27
Jun-13-19Initiated Mizuho Buy
Jun-07-19Initiated ROTH Capital Neutral $20
May-31-19Initiated Guggenheim Buy
May-24-19Resumed Citigroup Buy $26
Mar-28-19Initiated SVB Leerink Outperform $20
Jan-03-19Downgrade Stephens Overweight → Equal-Weight
Nov-05-18Initiated Jefferies Buy
Aug-01-18Initiated Citigroup Buy $20
Mar-06-18Downgrade H.C. Wainwright Buy → Neutral $12
Dec-18-17Initiated Piper Jaffray Overweight $10
Oct-12-17Resumed H.C. Wainwright Buy $7
Feb-07-20 08:00AM  Fate Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Feb-05-20 11:52AM  Steven Cohen Renews His Interest in Verastem GuruFocus.com
Jan-16-20 06:15AM  Fate Therapeutics (NASDAQ:FATE) Shareholders Have Enjoyed A Whopping 682% Share Price Gain Simply Wall St.
Jan-13-20 08:00AM  Fate Therapeutics Announces Expansion of FT516 Clinical Investigation and Publication of Preclinical Data in the Journal Blood GlobeNewswire
Jan-03-20 10:44AM  3 Top Drug Stocks to Own In 2020 InvestorPlace
Dec-13-19 02:18PM  Edited Transcript of FATE earnings conference call or presentation 5-Nov-19 10:00pm GMT Thomson Reuters StreetEvents
Dec-11-19 09:41AM  Biotech Stock Roundup: ASH Data in Focus, Amgen Gets FDA Nod to Remicade Biosimilar Zacks
Dec-10-19 09:52AM  Fate Therapeutics Presents its First Off-the-shelf, iPSC-derived CAR T-Cell Cancer Immunotherapy Program at ASH Annual Meeting GlobeNewswire
09:48AM  Fate (FATE) Announces Encouraging Data on Immunotherapies Zacks
09:07AM  Company News for Dec 10, 2019 Zacks
Dec-09-19 04:19PM  Here Are The Winners From The Year's Biggest Hematology Meeting Investor's Business Daily +41.33%
02:16PM  Wells Fargo Upgrades Fate Therapeutics On Induced Pluripotent Stem Cell Outlook Benzinga
11:04AM  Fate Therapeutics' stock rises on early-stage cancer drug data MarketWatch
Dec-08-19 07:28PM  Hedge Funds Have Never Been This Bullish On Fate Therapeutics Inc (FATE) Insider Monkey
10:39AM  Fate Therapeutics Announces New Preclinical Data for FT596 Off-the-Shelf, iPSC-derived CAR NK Cell Cancer Immunotherapy GlobeNewswire
Dec-07-19 08:40AM  Fate Therapeutics Announces Clinical Data from Landmark Phase 1 Studies of First-ever Universal, Off-the-shelf, iPSC-derived NK Cell Cancer Immunotherapy Programs GlobeNewswire
Dec-02-19 05:49AM  Is Fate Therapeutics (NASDAQ:FATE) A Risky Investment? Simply Wall St. -9.22%
Nov-27-19 04:01PM  Fate Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference GlobeNewswire
Nov-14-19 04:01PM  Fate Therapeutics to Present at the Jefferies 2019 London Healthcare Conference GlobeNewswire
Nov-06-19 09:01AM  Fate Therapeutics Announces Six Presentations at the 2019 ASH Annual Meeting GlobeNewswire -14.74%
Nov-05-19 07:25PM  Fate Therapeutics (FATE) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:05PM  Fate Therapeutics Reports Third Quarter 2019 Financial Results and Highlights Operational Progress GlobeNewswire
Oct-29-19 04:01PM  Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2019 Financial Results GlobeNewswire
Oct-28-19 07:44PM  Hedge Funds Have Never Been More Bullish On Fate Therapeutics Inc (FATE) Insider Monkey
Oct-18-19 08:12AM  What Kind Of Shareholder Owns Most Fate Therapeutics, Inc. (NASDAQ:FATE) Stock? Simply Wall St. -7.15%
05:57AM  Have Fate Therapeutics, Inc. (NASDAQ:FATE) Insiders Been Selling Their Stock? Simply Wall St.
Oct-01-19 01:48PM  Stifel Bullish On Iovance And Fate Therapeutics, Neutral On Bluebird Bio Benzinga -6.37%
Sep-30-19 08:00AM  Fate Therapeutics Announces the Opening of its cGMP Manufacturing Facility Dedicated to iPSC-derived Cell Therapies GlobeNewswire
Sep-18-19 04:01PM  Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares GlobeNewswire
Sep-12-19 07:38AM  The Daily Biotech Pulse: Ardelyx Awaits Ruling On Constipation Drug, Double Dose Of Good News For Roche, Tocagen Flunks Brain Cancer Study Benzinga -5.11%
12:53AM  Fate Therapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire
Sep-11-19 04:01PM  Fate Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire
Sep-10-19 11:06AM  Is Fate Therapeutics, Inc.'s (NASDAQ:FATE) CEO Paid At A Competitive Rate? Simply Wall St. +8.65%
Sep-04-19 10:02AM  Biotech Stock Roundup: REGN Wins Against AMGN, VRTX to Acquire Semma & More Zacks
Sep-03-19 08:01AM  Fate Therapeutics Announces FDA Clearance of IND Application for FT596 Off-the-Shelf, iPSC-derived CAR NK Cell Cancer Immunotherapy GlobeNewswire
Aug-29-19 08:00AM  Fate Therapeutics to Present at 2019 Wells Fargo Healthcare Conference GlobeNewswire
Aug-14-19 08:00AM  Fate Therapeutics Announces Issuance of Foundational U.S. Patent Covering iPSC-derived CAR T Cells GlobeNewswire
Aug-09-19 11:50AM  Edited Transcript of FATE earnings conference call or presentation 6-Aug-19 9:00pm GMT Thomson Reuters StreetEvents
Aug-07-19 12:20PM  Fate Therapeutics, Inc. (FATE) Q2 2019 Earnings Call Transcript Motley Fool -6.51%
Aug-06-19 06:35PM  Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates Zacks
03:00PM  Fate Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Jul-31-19 01:48PM  Steven Cohen Charges Into Chiasma GuruFocus.com
Jul-30-19 04:01PM  Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2019 Financial Results GlobeNewswire
Jul-29-19 10:34AM  Will Fate Therapeutics (FATE) Report Negative Q2 Earnings? What You Should Know Zacks
Jul-26-19 09:39AM  Introducing Fate Therapeutics (NASDAQ:FATE), The Stock That Soared 948% In The Last Three Years Simply Wall St.
Jul-17-19 04:01PM  Fate Therapeutics Announces the Appointment of Dr. Shefali Agarwal to its Board of Directors GlobeNewswire
Jul-08-19 08:15AM  Are Natural Killer Cells the Next Big Thing in Immunotherapy? Motley Fool
Jun-19-19 06:02PM  Hedge Funds Have Never Been This Bullish On Fate Therapeutics Inc (FATE) Insider Monkey
Jun-05-19 05:06AM  Edited Transcript of FATE earnings conference call or presentation 7-May-19 9:00pm GMT Thomson Reuters StreetEvents
May-30-19 04:05PM  Fate Therapeutics to Present at the Jefferies 2019 Healthcare Conference GlobeNewswire
May-29-19 08:40AM  Fate Therapeutics (FATE) Surges: Stock Moves 6.8% Higher Zacks
07:24AM  What You Must Know About Fate Therapeutics, Inc.'s (NASDAQ:FATE) Beta Value Simply Wall St.
May-07-19 10:41PM  Fate Therapeutics, Inc. (FATE) Q1 2019 Earnings Call Transcript Motley Fool -5.19%
06:15PM  Fate Therapeutics (FATE) Reports Q1 Loss, Misses Revenue Estimates Zacks
05:07PM  Fate Therapeutics: 1Q Earnings Snapshot Associated Press
04:01PM  Fate Therapeutics Reports First Quarter 2019 Financial Results and Highlights Operational Progress GlobeNewswire
May-03-19 11:23AM  Is Fate Therapeutics Inc (FATE) A Good Stock To Buy? Insider Monkey
Apr-30-19 04:05PM  Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2019 Financial Results GlobeNewswire
Apr-24-19 08:00AM  Fate Therapeutics Announces Five Presentations at the American Society of Gene & Cell Therapy 22nd Annual Meeting GlobeNewswire
Apr-18-19 08:01AM  Fate Therapeutics Appoints Wayne Chu, M.D. as Vice President, Clinical Development GlobeNewswire
Apr-02-19 08:00AM  Fate Therapeutics Announces First Patient Treated with iPSC-derived NK Cell Cancer Immunotherapy FT500 Successfully Completes Initial Safety Assessment GlobeNewswire
Apr-01-19 08:01AM  Fate Therapeutics Presents Late-Breaking Preclinical Data Highlighting Unique Advantages of Clonal Master Engineered iPSC Lines for Off-the-Shelf CAR T-cell Therapy at 2019 AACR Annual Meeting GlobeNewswire
Mar-26-19 12:12PM  What Do Analysts Think About Fate Therapeutics, Inc.s (NASDAQ:FATE) Earnings Trajectory? Simply Wall St. +5.39%
Mar-18-19 08:00AM  Fate Therapeutics Announces the Appointment of Karin Jooss, Ph.D. to its Board of Directors GlobeNewswire
Mar-11-19 02:05PM  Edited Transcript of FATE earnings conference call or presentation 5-Mar-19 10:00pm GMT Thomson Reuters StreetEvents
Mar-06-19 01:19AM  Fate Therapeutics Inc (FATE) Q4 2018 Earnings Conference Call Transcript Motley Fool
Mar-05-19 04:01PM  Fate Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Operational Progress GlobeNewswire
03:00PM  Fate Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Feb-28-19 04:43PM  Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
10:43AM  Cronos (CRON) to Report Q4 Earnings: What's in the Cards? Zacks
Feb-25-19 10:30AM  Fate Therapeutics (FATE) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks +12.83%
07:30AM  Market Trends Toward New Normal in Nuance Communications, Fate Therapeutics, Hamilton Lane, InflaRx N.V, Enerplus, and ManTech International Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Feb-22-19 08:00AM  Fate Therapeutics to Present at the 8th Annual SVB Leerink Global Healthcare Conference GlobeNewswire
Feb-20-19 08:00AM  Fate Therapeutics Appoints Sarah Cooley, M.D., M.S. as Senior Vice President, Clinical Translation GlobeNewswire
Feb-07-19 04:01PM  Fate Therapeutics to Present at Guggenheim Healthcare Talks Idea Forum Oncology Day GlobeNewswire -6.06%
Feb-06-19 08:37AM  Fate Therapeutics stock up 11% after FDA clears IND application MarketWatch
08:00AM  Fate Therapeutics Announces FDA Clearance of IND Application for Worlds First Cell Therapy Derived from an Engineered Pluripotent Stem Cell GlobeNewswire
Jan-22-19 11:52AM  Why Fate Therapeutics, Inc.s (NASDAQ:FATE) CEO Pay Matters To You Simply Wall St. -7.36%
Dec-19-18 12:04AM  Fate Therapeutics Inc (FATE) Hedge Funds Are Snapping Up Insider Monkey -6.05%
Dec-04-18 09:11AM  Fate Therapeutics Presents Off-the-Shelf CAR T and NK Cell Cancer Immunotherapy Pipeline at ASH Annual Meeting GlobeNewswire
Dec-03-18 04:01PM  Fate Therapeutics Secures Exclusive Option to Novel Humanized anti-BCMA CAR Constructs for Development of iPSC-derived Cell Products GlobeNewswire +10.48%
08:44AM  Fate Therapeutics (FATE) Jumps: Stock Rises 8.9% Zacks
07:40AM  Investor Expectations to Drive Momentum within Virtu Financial, Fate Therapeutics, Tandem Diabetes Care, Eli Lilly, Griffon, and Coherus BioSciences Discovering Underlying Factors of Influence GlobeNewswire
Nov-30-18 09:30AM  How Healthcare Is Evolving & Sector Stocks To Watch ACCESSWIRE +8.94%
09:10AM  Shares of Fate Therapeutics up 4.1% in premarket trade after FDA accepts IND application for potential cancer treatment MarketWatch
08:00AM  Fate Therapeutics Announces FDA Clearance of Landmark IND for FT500 iPSC-derived, Off-the-Shelf NK Cell Cancer Immunotherapy GlobeNewswire
Nov-28-18 04:22PM  3 Themes To Watch As Biopharmas 'Bring Some Excitement' In Blood Cancer Investor's Business Daily
Nov-16-18 10:35AM  What Kind Of Shareholder Appears On The Fate Therapeutics Incs (NASDAQ:FATE) Shareholder Register? Simply Wall St.
Nov-11-18 05:42PM  Fate Therapeutics Announces Encouraging Dose-Escalation Clinical Data of FATE-NK100 and Provides Regulatory Update on Landmark IND Application for FT500 GlobeNewswire
Nov-08-18 04:01PM  Fate Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire -10.00%
Nov-07-18 01:15AM  Edited Transcript of FATE earnings conference call or presentation 1-Nov-18 9:00pm GMT Thomson Reuters StreetEvents
Nov-01-18 06:40PM  Fate Therapeutics (FATE) Reports Q3 Loss, Lags Revenue Estimates Zacks +9.23%
05:35PM  Fate Therapeutics: 3Q Earnings Snapshot Associated Press
04:01PM  Fate Therapeutics Reports Third Quarter 2018 Financial Results and Highlights Operational Progress GlobeNewswire
09:01AM  Fate Therapeutics Announces Seven Presentations at the 2018 ASH Annual Meeting GlobeNewswire
Oct-29-18 04:01PM  Fate Therapeutics to Webcast Conference Call Reporting Third Quarter 2018 Financial Results GlobeNewswire -7.30%
Oct-25-18 03:55PM  3 Healthcare Stocks To Watch On Thursday ACCESSWIRE +17.68%
Oct-24-18 09:10AM  New Research: Key Drivers of Growth for Workhorse Group, Fate Therapeutics, Minerals Technologies, Tyson Foods, ZAGG, and USA Technologies Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire -9.89%
Oct-04-18 08:00AM  Fate Therapeutics Appoints Wen Bo Wang, Ph.D. as Senior Vice President, Technical Operations GlobeNewswire
Oct-03-18 07:00AM  This Biotech Stock Has Quadrupled and Its Top Shareholder Is Still Buying Barrons.com
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy comprising adaptive memory NK cells; FT500, an induced pluripotent stem cell (iPSC)-derived NK cell product candidate for the treatment of advanced solid tumors; FT516, an iPSC-derived non-cleavable CD16 engineered NK cell product candidate to treat hematologic malignancies and solid tumors; and FT596, a chimeric antigen receptor (CAR) T-cell therapy for patients with hematologic malignancies. The company's immuno-oncology product candidates also include FT538, an NK cell product candidate for treating multiple myeloma; and FT819, a CAR T-cell product candidate for the treatment of liquid and solid tumors. Its immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; and FT301, an immuno-regulatory cell product candidate for various disease indications, including graft-versus-host disease, multiple sclerosis, ulcerative colitis, and others. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; and strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Valamehr BahramChief Development OfficerFeb 03Option Exercise1.691,1531,94987,211Feb 04 04:01 PM
Wolchko J ScottPresident and CEOJan 30Option Exercise2.7025,00067,500444,969Feb 03 04:01 PM
Wolchko J ScottPresident and CEOJan 30Sale25.4525,000636,303419,969Feb 03 04:01 PM
Valamehr BahramChief Development OfficerJan 08Sale20.695,700117,94786,058Jan 10 04:03 PM
TAHL CINDYGeneral Counsel and SecretaryJan 08Sale20.725,700118,08599,518Jan 10 04:02 PM
Shoemaker Daniel DChief Scientific OfficerJan 08Sale20.705,700117,986143,091Jan 10 04:01 PM
Shoemaker Daniel DChief Scientific OfficerDec 30Option Exercise2.9025,00072,500148,791Jan 02 04:01 PM
Shoemaker Daniel DChief Scientific OfficerDec 30Sale19.5025,000487,427123,791Jan 02 04:01 PM
Wolchko J ScottPresident and CEODec 20Option Exercise2.7025,00067,500378,969Dec 23 04:02 PM
Wolchko J ScottPresident and CEODec 20Sale20.1725,000504,158353,969Dec 23 04:02 PM
Wolchko J ScottPresident and CEODec 19Option Exercise2.7025,00067,500378,969Dec 23 04:02 PM
Wolchko J ScottPresident and CEODec 19Sale20.0825,000501,898353,969Dec 23 04:02 PM
Valamehr BahramChief Development OfficerOct 15Sale14.186,20087,89166,758Oct 16 04:06 PM
Wolchko J ScottPresident and CEOOct 15Sale14.4421,017303,458353,969Oct 16 04:07 PM
TAHL CINDYGeneral Counsel and SecretaryOct 15Sale14.2410,200145,29280,218Oct 16 04:05 PM
Shoemaker Daniel DChief Scientific OfficerOct 15Sale14.2911,800168,593123,791Oct 16 04:04 PM
Redmile Group, LLCDirectorSep 16Buy17.50857,14315,000,00311,216,809Sep 17 04:22 PM
Nashat AmirDirectorAug 01Sale22.5330,866695,3927,539Aug 02 04:32 PM
Nashat AmirDirectorJul 31Sale22.5331,139701,6747,743Aug 02 04:32 PM
Nashat AmirDirectorJul 30Sale22.5190,1752,029,5607,949Jul 30 06:25 PM
Nashat AmirDirectorJul 29Sale22.503297,4038,545Jul 30 06:25 PM
Nashat AmirDirectorJul 26Sale22.5027,829626,1538,548Jul 30 06:25 PM
Nashat AmirDirectorJul 24Sale22.5119,866447,0988,732Jul 25 06:24 PM
Nashat AmirDirectorJul 23Sale22.5162,0331,396,0538,864Jul 25 06:24 PM
Nashat AmirDirectorJul 22Sale22.5248,7041,097,0199,275Jul 22 05:52 PM
Nashat AmirDirectorJul 19Sale22.501,05323,6939,598Jul 22 05:52 PM
Nashat AmirDirectorJul 18Sale22.5021,409481,7959,605Jul 22 05:52 PM
Shoemaker Daniel DChief Scientific OfficerJun 27Option Exercise2.9012,50036,250148,091Jun 28 04:02 PM
Shoemaker Daniel DChief Scientific OfficerJun 27Sale20.2112,500252,610135,591Jun 28 04:02 PM
Wolchko J ScottPresident and CEOMay 16Option Exercise1.6314,33523,366389,216May 17 06:27 PM
Wolchko J ScottPresident and CEOMay 16Sale19.3714,335277,684374,881May 17 06:27 PM
Wolchko J ScottPresident and CEOApr 18Option Exercise1.6311,45918,678381,724Apr 19 04:13 PM
Wolchko J ScottPresident and CEOApr 18Sale16.0111,459183,509374,881Apr 19 04:13 PM
Wolchko J ScottPresident and CEOApr 17Option Exercise1.638,54113,922382,330Apr 19 04:13 PM
Wolchko J ScottPresident and CEOApr 17Sale16.178,541138,132374,881Apr 19 04:13 PM
Shoemaker Daniel DChief Scientific OfficerMar 28Option Exercise2.9012,50036,250148,091Mar 29 04:01 PM
Shoemaker Daniel DChief Scientific OfficerMar 28Sale16.9412,500211,703135,591Mar 29 04:01 PM
Wolchko J ScottPresident and CEOMar 21Option Exercise1.6320,00032,600394,881Mar 22 04:01 PM
Wolchko J ScottPresident and CEOMar 21Sale17.6120,000352,160374,881Mar 22 04:01 PM
TAHL CINDYGeneral Counsel and SecretaryMar 01Option Exercise2.9025,00072,500115,418Mar 05 09:00 AM
TAHL CINDYGeneral Counsel and SecretaryMar 01Sale16.1525,000403,69890,418Mar 05 09:00 AM
TAHL CINDYGeneral Counsel and SecretaryFeb 25Option Exercise2.9025,00072,500115,418Feb 27 04:01 PM
TAHL CINDYGeneral Counsel and SecretaryFeb 25Sale16.0725,000401,82090,418Feb 27 04:01 PM
open in yahoo | open in reuters | open in google